Stock Scorecard

Stock Summary for Actinium Pharmaceuticals Inc (ATNM) - $1.52 as of 12/17/2025 8:37:52 AM EST

Total Score

10 out of 30

Safety Score

19 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ATNM

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ATNM

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ATNM

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ATNM

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ATNM (19 out of 100)

Stock Price Rating (Max of 10) 2
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for ATNM

ATNM Investors are Reminded of the Class Action Against Actinium Pharmaceuticals, Inc.: Contact Robbins LLP for Information About How to Become Lead Plaintiff for the Class 12/14/2025 9:09:00 PM
Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Br 12/12/2025 2:09:00 PM
Why Is Actinium Pharmaceuticals Stock Rising Today? 12/12/2025 2:05:00 PM
Why Is Actinium Pharmaceuticals Stock Rising Today? 12/12/2025 10:09:00 AM
Actinium Pharmaceuticals Advances Trop-2 Targeted Alpha Radiotherapy Into Phase 1/2 Trials in the U.S. and Australia 12/11/2025 2:09:00 PM
Actinium Pharmaceuticals (NYSEAMERICAN: ATNM) Begins European Phase 1 Trial of Nectin-4 Targeted Alpha Therapy for Multiple Solid Tumors 12/10/2025 12:09:00 PM
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Advances 12/9/2025 11:09:00 PM
Actinium Pharmaceuticals Advances ATNM-400 B7-H3 Candidate Into Phase 1 Clinical Trial in South Africa 12/8/2025 2:09:00 PM
ATNM-400 Targets B7-H3 and Is Being Studied in a Phase 1 Clinical Trial in South Africa 12/8/2025 2:09:00 PM
Jeri Kim: Thrilled to Join Actinium Pharmaceuticals as VP, Head of Solid Tumor Clinical Development 12/3/2025 5:20:00 AM

Financial Details for ATNM

Company Overview
Ticker ATNM
Company Name Actinium Pharmaceuticals Inc
Country USA
Description Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in New York that specializes in developing innovative therapies for hematologic malignancies, particularly in the realms of bone marrow transplantation and adoptive cell therapies. Leveraging its proprietary antibody-radionuclide conjugate platform, Actinium is committed to enhancing patient outcomes and addressing critical unmet needs in oncology. With a robust pipeline of therapeutic candidates and strategic partnerships, the company stands out as a promising investment opportunity for institutional investors looking for growth and innovation in the biopharmaceutical sector.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 9/30/2025
Next Earnings Date 3/13/2026

Stock Price History
Last Day Price 1.52
Price 4 Years Ago 6.01
Last Day Price Updated 12/17/2025 8:37:52 AM EST
Last Day Volume 312,430
Average Daily Volume 209,017
52-Week High 2.41
52-Week Low 1.03
Last Price to 52 Week Low 47.57%

Valuation Measures
Trailing PE N/A
Industry PE 23.33
Sector PE 104.08
5-Year Average PE -3.67
Free Cash Flow Ratio 0.89
Industry Free Cash Flow Ratio 15.84
Sector Free Cash Flow Ratio 23.00
Current Ratio Most Recent Quarter 7.96
Total Cash Per Share 1.71
Book Value Per Share Most Recent Quarter 0.44
Price to Book Ratio 3.42
Industry Price to Book Ratio 47.50
Sector Price to Book Ratio 21.07
Price to Sales Ratio Twelve Trailing Months 551.13
Industry Price to Sales Ratio Twelve Trailing Months 23.27
Sector Price to Sales Ratio Twelve Trailing Months 17.16
Analyst Buy Ratings 3
Analyst Strong Buy Ratings 1

Share Statistics
Total Shares Outstanding 31,195,900
Market Capitalization 47,417,768
Institutional Ownership 19.86%

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 21.66%
Reported EPS 12 Trailing Months -1.11
Reported EPS Past Year -0.89
Reported EPS Prior Year -1.27
Net Income Twelve Trailing Months -34,599,000
Net Income Past Year -38,243,000
Net Income Prior Year -48,818,000
Quarterly Revenue Growth YOY -100.00%
5-Year Revenue Growth -14.12%
Operating Margin Twelve Trailing Months -6,324.00%

Balance Sheet
Total Cash Most Recent Quarter 53,391,000
Total Cash Past Year 72,904,000
Total Cash Prior Year 76,677,000
Net Cash Position Most Recent Quarter 45,878,000
Net Cash Position Past Year 64,951,000
Long Term Debt Past Year 7,953,000
Long Term Debt Prior Year 10,130,000
Total Debt Most Recent Quarter 7,513,000
Equity to Debt Ratio Past Year 0.80
Equity to Debt Ratio Most Recent Quarter 0.65
Total Stockholder Equity Past Year 32,758,000
Total Stockholder Equity Prior Year 36,379,000
Total Stockholder Equity Most Recent Quarter 13,784,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months -25,042,000
Free Cash Flow Per Share Twelve Trailing Months -0.80
Free Cash Flow Past Year -33,083,000
Free Cash Flow Prior Year -47,488,000

Options
Put/Call Ratio 0.10
Has Options Options Chain
Liquidity Rating None

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 0.02
MACD Signal 0.00
20-Day Bollinger Lower Band 0.00
20-Day Bollinger Middle Band 0.00
20-Day Bollinger Upper Band 0.00
Beta -0.36
RSI 0.00
50-Day SMA 1.47
150-Day SMA 4.61
200-Day SMA 5.29

System
Modified 12/16/2025 5:54:23 PM EST